The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Open accessAbstract
Immune checkpoint inhibitors (ICPi) have revolutionized the treatment of many types of cancers.ICPis work by blocking pathways, called checkpoints, and these checkpoint pathways are mechanisms for the human immune system to control the immune response.The immune checkpoint proteins, cytotoxic T lymphocyte-associated 4 (CTLA-4) and programmed death 1 (PD-1), are receptors that are expressed on the surface of cytotoxic T cells that interact with their ligands-CD80/CD86 in the case of CTLA-4, and programmed death ligand-1 in the case of PD-1.These pathways can be co-opted to help cancer cells evade cytotoxic T cell-mediated death. 1 ICPis prevent receptors and ligands from binding to each other, thereby disrupting signaling.1 Currently, there are several ICPis that have been approved by the US Food and Drug Administration.Ipilimumab, an anti-CTLA-4 antibody, was the first agent approved for use in patients with advanced melanoma.2 Pembrolizumab and nivolumab target PD-1 and have been approved for the treatment of melanoma, metastatic non-small-cell lung cancer, head and neck squamous cancers, urothelial carcinoma, gastric adenocarcinoma, and mismatch repair-deficient solid tumors as well as classical Hodgkin lymphoma.2
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Self-citationDine, J., Gordon, R., Shames, Y., Kasler, M. K., & Barton-Burke, M. (2017) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon_4_17 · Cited by 214
Research works printed but not linked: 1
- Brahmer JR, J Clin Oncol
Cited by
Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00517-1 · Cited by 697
Update 2020: Management of Non-Small Cell Lung Cancer
Alexander, M., Kim, S. Y., & Cheng, H. (2020) · Lung · doi:10.1007/s00408-020-00407-5 · Cited by 648
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., Abudayyeh, A., Mamlouk, O., Motwani, S. S., Murakami, N., Herrmann, S. M., Manohar, S., Shirali, A. C., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070676 · Cited by 407
Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
Alduais, Y., Zhang, H., Fan, F., Chen, J., & Chen, B. (2023) · Medicine · doi:10.1097/md.0000000000032899 · Cited by 347
Santini, F. C., Rizvi, H., Plodkowski, A. J., Ni, A., Lacouture, M. E., Gambarin-Gelwan, M., Wilkins, O., Panora, E., Halpenny, D. F., Long, N. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0755 · Cited by 331
Metadata
- Authors
- Brahmer, J. R., Lacchetti, C., & Thompson, J. A.
- Venue
- Journal of Oncology Practice
- Published
- 2018-04
- Volume
- 14
- Issue
- 4
- Pages
- 247-249
- ISSN
- 1554-7477 (ISSN-L)
- 1935-469X
- OpenAlex
- W2789465165
- Cited by
- 377
- References
- 2
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. https://app.cochat.ai/papers/10.1200/jop.18.00005
- The paper
- Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice. https://doi.org/10.1200/jop.18.00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.